Hepatitis A Surveillance and Vaccine Use in China from 1990 Through 2007
Overview
Authors
Affiliations
Background: Hepatitis A vaccines have been highly effective in preventing hepatitis A. To investigate the epidemiology of hepatitis A in China after hepatitis A vaccine became available, we reviewed reported cases of hepatitis A and the use of hepatitis A vaccine in China during the period from 1990 through 2007.
Methods: Data from the National Notifiable Disease Reporting System from 1990 to 2007 and the Emergency Events Reporting System from 2004 to 2007 were reviewed and epidemiologic characteristics analyzed. Hepatitis A vaccine distribution between 1992 and 2007 was also reviewed.
Results: The incidence of hepatitis A has declined by 90% since 1990, from 56 to 5.9 per 10(5)/year. Declines in age-specific incidence were seen in all age groups, most dramatically among children younger than 10 years. Disease incidence still varies substantially: poorer western provinces have had the highest incidences since 2000. In high-incidence provinces, children younger than 10 years continue to have a high disease incidence. Only 50% of cases were laboratory-confirmed, and only 3% occurred in reported local outbreaks. Over 156 million doses of hepatitis A vaccine have been distributed since 1992, and use has continued to increase since 2003.
Conclusions: Incidence of hepatitis A has decreased in all age groups, likely due to changing socioeconomic conditions and increasing hepatitis A vaccine use. Nevertheless, western populations remain at high risk, with transmission predominantly occurring among children. The epidemiology of hepatitis A transmission is not well understood. Improved surveillance with better laboratory confirmation is needed to monitor the impact of universal hepatitis A vaccination of young children; this strategy began to be implemented in 2008.
Ming B, Li L, Huang H, Ma J, Shi C, Xu X JMIR Public Health Surveill. 2024; 10:e53982.
PMID: 38416563 PMC: 10938223. DOI: 10.2196/53982.
The Shifting Epidemiology of Hepatitis A in the World Health Organization Western Pacific Region.
Gloriani N, de Paz-Silava S, Allison R, Takashima Y, Avagyan T Vaccines (Basel). 2024; 12(2).
PMID: 38400187 PMC: 10891653. DOI: 10.3390/vaccines12020204.
Wu Y, Wang P, Huang Y, Chen J, Chang Y, Li J BMJ Glob Health. 2024; 9(2).
PMID: 38320803 PMC: 10859990. DOI: 10.1136/bmjgh-2023-013444.
Ming B, Yang Z, Yan Z, Shi C, Xu X, Li L Infect Dis Poverty. 2023; 12(1):56.
PMID: 37231511 PMC: 10208907. DOI: 10.1186/s40249-023-01104-0.
Li Y, Zhang B, Zhang X, Fan S, Fei L, Yang C BMC Infect Dis. 2022; 22(1):663.
PMID: 35915398 PMC: 9341093. DOI: 10.1186/s12879-022-07651-5.